Used in cancer immunotherapy to modulate T-cell activity by targeting the ICOS (inducible T-cell co-stimulator) receptor. It helps enhance anti-tumor immune responses by promoting the activation and proliferation of effector T cells while potentially suppressing regulatory T cell function. Feladilimab is being investigated in clinical trials as a monotherapy or in combination with other immunotherapies, such as PD-1 inhibitors, for the treatment of advanced solid tumors. Its application aims to overcome immune evasion by tumors, making it a candidate for treating cancers like melanoma, non-small cell lung cancer, and others where immune checkpoint pathways play a critical role.